Skip to main content

Kenneth Thirstrup, PhD

Research Scientist, Section of Early Target Pharmacology and Physiology at H. Lundbeck A/S

Location: Valby Denmark

Kenneth Thirstrup received his MSc degree from the University of Copenhagen, where he also received his PhD in molecular pharmacology with focus on molecular mechanisms of G-protein-coupled receptor activation.

From 1997-2001 Dr. Thirstrup worked in the biotech industry, first as Chief Molecular Biologist in the startup biotech company Display Systems Biotech, and later as project manager at Neurosearch with focus on developing and using new genomics technologies to identify disease targets.

Since 2002, Dr. Thirstrup has worked within the pharmaceutical industry at H. Lundbeck. His research interests are focused on early target identification within Parkinson’s disease and driving target validation toward pre-clinical pharmacological evaluation.

Associated Grants

  • GPR88, a new PD target involved in the modulation of basal ganglia circuitry


  • Hif Prolyl Hydroxylase Inhibitors: New Treatment Potential against Parkinson's Disease


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.